Search

Your search keyword '"Tsai, James Y."' showing total 13 results
Start Over Author "Tsai, James Y."
13 results on '"Tsai, James Y."'

7. Phase I Study of Docetaxel, Capecitabine, and Carboplatin in Metastatic Esophagogastric Cancer

Author

Tsai, James Y., primary, Iannitti, David, additional, Berkenblit, Anna, additional, Akerman, Paul, additional, Nadeem, Ahmed, additional, Rathore, Ritesh, additional, Harrington, David, additional, Roye, Dean, additional, Miner, Thomas, additional, Barnett, John M., additional, Maia, Christine, additional, Stuart, Keith, additional, and Safran, Howard, additional

Published
2005
Full Text
View/download PDF

8. Herceptin and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/neu

Author

Safran, Howard, primary, Iannitti, David, additional, Ramanathan, Ramesh, additional, Schwartz, Jonathan D., additional, Steinhoff, Margaret, additional, Nauman, Chris, additional, Hesketh, Paul, additional, Rathore, Ritesh, additional, Wolff, Robert, additional, Tantravahi, Umadevi, additional, Hughes, Marilyn, additional, Maia, Chris, additional, Pasquariello, Terry, additional, Goldstein, Lisa, additional, King, Thomas, additional, Tsai, James Y., additional, and Kennedy, Teresa, additional

Published
2004
Full Text
View/download PDF

12. Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study.

Author

Safran, Howard, DiPetrillo, Thomas, Nadeem, Ahmed, Steinhoff, Margaret, Tantravahi, Umadevi, Rathore, Ritesh, Wanebo, Harold, Hughes, Marilyn, Maia, Chris, Tsai, James Y., Pasquariello, Terry, Pepperell, John R., Cioffi, William, Kennedy, Teresa, Reeder, Laurie, Ng, Thomas, Adrian, Alyn, Goldstein, Lisa, Chak, Bapsi, and Choy, Hak

Subjects
TRASTUZUMAB, PACLITAXEL, CISPLATIN, RADIOTHERAPY, ESOPHAGEAL cancer, ADENOCARCINOMA
Abstract

Purpose: To conduct a phase I study incorporating trastuzumab with paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus.Methods and Materials: Patients with adenocarcinoma of the esophagus without distant organ metastases were eligible. All patients received cisplatin 25 mg/m2 and paclitaxel 50 mg/m2 weekly for 6 weeks with radiation 50.4 Gy. HER-2/neu-positive patients (2+/3+ by immunohistochemistry) received weekly trastuzumab at dose levels of 1, 1.5, or 2 mg/kg weekly for 5 weeks after an initial bolus of 2, 3, or 4 mg/kg, respectively. HER-2/neu-negative patients received the same chemoradiation without trastuzumab as a control for toxicity. Dose-limiting toxicities were defined as grade 3 esophageal, cardiac, or pulmonary toxicity.Results: Twelve of 36 screened patients (33%) overexpressed HER-2/neu by immunohistochemistry (seven 3+ and five 2+). Eight of 12 patients with HER-2/neu overexpression by IHC had an increase in the number of HER-2/neu genes, six from amplification of the HER-2/ neu gene and two were hypderdiploid for chromosome 17. Thirty patients were enrolled (12 HER-2/neu-positive and 18 HER-2/neu-negative controls). No increase in toxicity was seen with the addition of trastuzumab. One of 12 patients in the trastuzumab arm and 8 of 17 in the control arm had grade 3 esophagitis (p < or = .026). Mean left ventricular ejection fraction for the trastuzumab group was 57% before treatment and 56% after treatment.Conclusion: HER-2/neu is overexpressed in approximately one-third of esophageal adenocarcinomas. Trastuzumab can be added at full dose to cisplatin, paclitaxel, and radiation. Future studies of trastuzumab in esophageal adenocarcinoma are indicated. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

13. Chemotherapy for pancreatic cancer.

Author

Tsai JY, Nadeem A, and Safran H

Subjects
Antimetabolites, Antineoplastic therapeutic use, Combined Modality Therapy, Disease Progression, Drug Therapy, Combination, ErbB Receptors antagonists & inhibitors, Humans, Pancreatic Neoplasms pathology, Pancreatic Neoplasms radiotherapy, Radiotherapy, Adjuvant, Antineoplastic Agents therapeutic use, Pancreatic Neoplasms drug therapy
Published
2004

Catalog

Books, media, physical & digital resources
See catalog results